Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study to Evaluate the Safety and Tolerability of Pyridorin (Pyridoxamine Dihydrochloride) in Patients With Diabetic Nephropathy Associated With Type 1 or Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Dec 2014
Price :
$35
*
At a glance
- Drugs Pyridoxamine (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions; Therapeutic Use
- Sponsors BioStratum
- 05 Nov 2010 New trial record.